RxDoctor Payments Data

Douglas Paone, MD

Internal Medicine · Naples, FLNPI 1336245190

Payments from drug & device makers

$327,568in general payments, 2019–2025

Across 68 payments — averaging $4817.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$327K
  • AstraZeneca$197
  • Kowa Pharmaceuticals America, Inc.$114
  • Boehringer Ingelheim$111
  • GSK$69
  • Medtronic$64
  • plus $288 from 7 others

What the payments were for

  • Food & beverage$863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$327,568 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$186,681
Medicare patients
329
Services billed
3,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$169,487
JardianceEmpagliflozin64$86,892
OzempicSemaglutide49$65,284
EntrestoSacubitril/Valsartan35$38,522
MyrbetriqMirabegron33$36,509
XareltoRivaroxaban19$30,083
FarxigaDapagliflozin Propanediol11$16,598
Breo ElliptaFluticasone/Vilanterol14$15,794
MounjaroTirzepatide13$13,711
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,026
TradjentaLinagliptin11$9,976
Dexlansoprazole DrDexlansoprazole22$8,196
Memantine Hcl ErMemantine Hcl14$4,419
AlvescoCiclesonide12$3,425
SynthroidLevothyroxine Sodium38$2,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$326,724$169,487134 claims
Boehringer IngelheimJardiance, Tradjenta$111$96,86875 claims
Novo NordiskOzempic$56$65,28449 claims
NovartisEntresto$42$38,52235 claims
Johnson & JohnsonXarelto$42$30,08319 claims
GSKBreo Ellipta, Trelegy Ellipta$69$28,81932 claims
AstraZenecaFarxiga$197$16,59811 claims
Lilly USA, LLCMounjaro$31$13,71113 claims
AbbVieSynthroid$33$2,75038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →